Which CJC-1295 (No DAC) Vial Size Should a Lab Order?

At a glance: Matching vial mass to research throughput

Choosing the correct CJC-1295 (no dac) vial size mg depends primarily on your laboratory's active incubation schedules and aliquot turnover rates. Because CJC-1295 (No DAC) lacks the Drug Affinity Complex (DAC) modification, its half-life in aqueous solution following reconstitution is significantly shorter than its DAC-bound counterpart, making post-reconstitution hydrolytic degradation a core variable in experimental design.

For small-scale in vitro binding assays or low-frequency cell culture exposures, 2 mg or 5 mg vials typically minimize peptide degradation and avoid unnecessary waste. High-throughput automated screening environments running daily assays benefit more from 10 mg bulk configurations to ensure consistent batch concentration across multi-well plates. All orders from PX1 Research include lot-specific analytical documentation ensuring baseline purity before reconstitution.

What is CJC-1295 (No DAC) and how does it function in research?

CJC-1295 (No DAC), also classified as Modified GRF (1-29), is a synthetic tetrasubstituted peptide analog of human growth hormone-releasing hormone (GHRH). Preclinical studies show that this compound binds selectively to the GHRH receptor on anterior pituitary somatotropes. In laboratory models, it acts as a functional GHRH analog, stimulating adenylate cyclase and downstream cAMP-dependent signaling cascades to promote endogenous growth hormone synthesis and secretion.

In cell culture and animal models, researchers study cjc 1295 to analyze pulse-dependent GH release and downstream insulin-like growth factor 1 (IGF-1) expression associated with tissue repair research. Unlike wild-type GHRH (1-29), cjc no dac features amino acid substitutions at positions 2, 8, 15, and 27 (D-Ala, Gln, Ala, and Leu, respectively) that confer resistance to rapid enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV).

When designing comparative endocrine trials, researchers frequently contrast non-conjugated GHRH variants with long-acting formulations such as CJC-1295 with DAC or full-length secretagogues like Sermorelin to map receptor activation kinetics and desensitization thresholds.

Why does vial milligram size matter for CJC-1295 (No DAC) assays?

In peptide chemistry, physical mass selection directly dictates post-reconstitution shelf life and concentration consistency. Once lyophilized CJC-1295 (No DAC) is reconstituted with a sterile aqueous diluent—such as bacteriostatic water or sterile normal saline—the peptide chain becomes vulnerable to chemical degradation pathways, including deamidation, oxidation, and peptide bond hydrolysis.

If a laboratory orders an oversized CJC-1295 (no dac) vial size mg for a low-volume study, reconstituted liquid solution may sit in cold storage for several weeks. Repeated thermal cycling, micro-vibrations, and fluid draw events accelerate peptide aggregation and loss of monomeric purity. Selecting a vial mass aligned with your 7-to-14-day consumption window prevents experimental drift caused by altered effective concentrations.

Selecting 2 mg vs 5 mg vs 10 mg CJC-1295 (No DAC) vials

To select the proper mass, compare your protocol's required working concentration against standard laboratory reconstituted volume constraints:

• **2 mg Vials:** Ideal for small-scale pilot studies, exploratory receptor-binding assays, or low-frequency animal model dosing. Reconstituting 2 mg in 1 mL or 2 mL of diluent yields highly manageable working concentrations (1 mg/mL or 2 mg/mL) without requiring prolonged liquid storage.

• **5 mg Vials:** The standard operational benchmark for mid-sized comparative research workflows. A 5 mg vial supports multi-week assay runs across multiple cell culture plates while staying safely within peak stability windows. You can buy 5 mg vials of CJC-1295 No DAC directly from PX1 Research with validated batch purity.

• **10 mg Vials:** Optimized for high-throughput automated platforms, continuous organoid perfusion studies, or large-cohort rodent trials. Ordering 10 mg configurations lowers container unit volume overhead and simplifies master-mix preparation for high-volume automated liquid handlers.

Evaluating co-administration protocols: CJC-1295 (No DAC) and Ipamorelin

In dual-pathway secretagogue studies, research protocols often combine a GHRH analog with a selective Growth Hormone Secretagogue Receptor (GHSR) agonist. A frequently documented pairing is cjc ipamorelin, which investigates the synergistic activation of pituitary somatotropes through simultaneous GHRH receptor and ghrelin receptor stimulation.

When coordinating dual-peptide assays, investigators should match the milligram mass of CJC-1295 (No DAC) with corresponding quantities of Ipamorelin. Choosing matching vial capacities (e.g., pairing 5 mg CJC-1295 No DAC with 5 mg Ipamorelin) simplifies stoichiometric calculations and ensures both reconstituted working solutions remain fresh over identical experimental schedules.

Reconstitution, solution stability, and waste minimization

Lyophilized CJC-1295 (No DAC) exhibits high stability when stored at -20°C in a desiccated environment prior to reconstitution. However, once reconstituted for in vitro or preclinical applications, solution degradation kinetics accelerate. Data indicate that at 4°C refrigeration, aqueous solutions maintain optimal stability for up to 14 to 21 days before minor hydrolysis products begin appearing on HPLC chromatograms.

To minimize peptide loss and maintain consistent assay conditions:

1. Reconstitute using high-purity bacteriostatic water (0.9% benzyl alcohol) for multi-draw vials, or sterile 0.9% sodium chloride for immediate single-use cell culture assays.

2. Gently swirl the vial during dissolution; avoid vigorous vortexing or shaking, which can induce physical shear stress and peptide denaturation.

3. Aliquot reconstituted stock into sub-volumes using low-protein-binding polypropylene microcentrifuge tubes if the full volume will not be consumed within 7 days.

4. Avoid repeated freeze-thaw cycles. Freezing reconstituted working solutions causes cryo-concentration gradients that destabilize delicate peptide bonds.

Vendor evaluation criteria for CJC-1295 (No DAC) procurement

Sourcing high-purity reagents requires stringent vendor screening. Laboratories should evaluate peptide suppliers across six critical operational criteria to protect dataset integrity:

• **Purity Verification:** Demand lot-specific High-Performance Liquid Chromatography (HPLC) showing monomeric purity strictly ≥98.0%.

• **Sourcing & Synthesis:** Verify domestic synthesis facilities with rigorous quality management protocols rather than unverified overseas re-packagers.

• **Lot Traceability:** Ensure every vial carries an unalterable batch number matching a publicly accessible Certificate of Analysis (COA).

• **Endotoxin Data:** Require quantitative Mass Spectrometry (MS) and Chromogenic LAL endotoxin testing (ideally <0.01 EU/mg) to prevent non-specific inflammatory responses in cellular assays.

• **Shipping Speed:** Insist on rapid cold-chain or expedited dispatch with temperature-monitored packaging to prevent thermal degradation during transit.

• **Technical Support:** Work with suppliers providing dedicated PhD-level technical support capable of reviewing analytical data and reconstitution chemistry.

Red flags when sourcing CJC-1295 (No DAC) from research vendors

Substandard peptide reagents introduce uncontrolled variables into laboratory models, wasting valuable time and resources. When vetting vendor catalogs, look out for these operational red flags:

• **Generic or Shared COAs:** Vendors presenting a single 'representative' Certificate of Analysis across multiple batches rather than providing lot-specific HPLC and MS reports.

• **Absence of Endotoxin Testing:** Failing to publish endotoxin levels. Bacterial endotoxins (LPS) cause severe cell culture toxicity and skew cellular viability data.

• **Unexplained Mass Discrepancies:** Vials that vary visually in lyophilized cake size or lack vacuum sealing, indicating inconsistent lyophilization cycles or fill volumes.

• **Exaggerated Marketing or Non-Research Claims:** Vendors making claims regarding human consumption, cosmetic use, or therapeutic dosing. Legitimate suppliers maintain strict adherence to in vitro and laboratory research standards.

Ordering from PX1 Research

PX1 Research provides laboratory-grade CJC-1295 (No DAC) engineered specifically for high-precision analytical assays and preclinical research models. Each shipment contains vacuum-sealed lyophilized vials produced via advanced solid-phase peptide synthesis (SPPS), ensuring consistent bioactivity and lot-to-lot uniformity.

We offer CJC-1295 (No DAC) in standardized 2 mg, 5 mg, and 10 mg vial sizes to match your specific assay throughput. Orders placed before 3:00 PM EST (M–F) ship same-day from our dual dispatch hubs in California and Arizona via tracked domestic shipping. Every batch includes full access to independent third-party HPLC, MS, and LAL endotoxin testing documentation.

Browse our full catalog to order CJC-1295 No DAC online or explore our complete library of research peptides for your lab's ongoing research needs.